Reviewers: YANG Chun-li, ZOU Li-qun. ECHELON-2 Study: Curative Effect Analysis of Brentuximab Vedotin with CHP Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma[J]. Journal of Evidence-Based Medicine, 2020, 20(2): 85-88. DOI: 10.12019/j.issn.1671-5144.2020.02.006
|
Citation:
|
Reviewers: YANG Chun-li, ZOU Li-qun. ECHELON-2 Study: Curative Effect Analysis of Brentuximab Vedotin with CHP Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma[J]. Journal of Evidence-Based Medicine, 2020, 20(2): 85-88. DOI: 10.12019/j.issn.1671-5144.2020.02.006
|
Reviewers: YANG Chun-li, ZOU Li-qun. ECHELON-2 Study: Curative Effect Analysis of Brentuximab Vedotin with CHP Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma[J]. Journal of Evidence-Based Medicine, 2020, 20(2): 85-88. DOI: 10.12019/j.issn.1671-5144.2020.02.006
|
Citation:
|
Reviewers: YANG Chun-li, ZOU Li-qun. ECHELON-2 Study: Curative Effect Analysis of Brentuximab Vedotin with CHP Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma[J]. Journal of Evidence-Based Medicine, 2020, 20(2): 85-88. DOI: 10.12019/j.issn.1671-5144.2020.02.006
|
DownLoad: